PE20190380A1 - Composiciones para activacion de nrf2 mejorada y sus metodos de uso - Google Patents

Composiciones para activacion de nrf2 mejorada y sus metodos de uso

Info

Publication number
PE20190380A1
PE20190380A1 PE2018000340A PE2018000340A PE20190380A1 PE 20190380 A1 PE20190380 A1 PE 20190380A1 PE 2018000340 A PE2018000340 A PE 2018000340A PE 2018000340 A PE2018000340 A PE 2018000340A PE 20190380 A1 PE20190380 A1 PE 20190380A1
Authority
PE
Peru
Prior art keywords
extract
luteolin
specified
enhanced
compositions
Prior art date
Application number
PE2018000340A
Other languages
English (en)
Inventor
Brooks Michael Hybertson
Joe Milton Mccord
Original Assignee
Pathways Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathways Bioscience Llc filed Critical Pathways Bioscience Llc
Publication of PE20190380A1 publication Critical patent/PE20190380A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: i) EXTRACTO DE ROMERO QUE ESTA ESPECIFICADO AL 5-10% DE CARNOSOL, ii) EXTRACTO DE JENGIBRE QUE ESTA ESPECIFICADO AL 10-20% DE 6-SHOGAOL, iii) LUTEOLINA QUE ESTA ESPECIFICADO AL 95-99% DE LUTEOLINA, iv) EXTRACTO DE CARDO LECHERO, Y v) EXTRACTO DE BACOPA MONNIERI; DONDE LA RELACION ENTRE LOS CINCO COMPONENTES ES DE 10:5:1:30:48 (P/P). DICHA COMPOSICION COMPRENDE DOS O MAS PRODUCTOS FITOQUIMICOS TALES COMO CARNOSOL, ACIDO CARNOSICO, SHOGAOL, GINGEROL, LUTEOLINA Y WITAFERINA A, EN UNA CANTIDAD EFICAZ PARA ACTIVAR LA VIA DE Nrf2 (FACTOR 2 RELACIONADO CON FACTOR NUCLEAR ERITROIDE 2), SIENDO UTIL PARA PREVENIR Y/O TRATAR CONDICIONES DE SALUD ASOCIADAS CON INFLAMACION O ESTRES OXIDATIVO
PE2018000340A 2015-09-03 2016-09-02 Composiciones para activacion de nrf2 mejorada y sus metodos de uso PE20190380A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214175P 2015-09-03 2015-09-03
US201662355810P 2016-06-28 2016-06-28

Publications (1)

Publication Number Publication Date
PE20190380A1 true PE20190380A1 (es) 2019-03-08

Family

ID=58188643

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000340A PE20190380A1 (es) 2015-09-03 2016-09-02 Composiciones para activacion de nrf2 mejorada y sus metodos de uso

Country Status (9)

Country Link
US (1) US11413269B2 (es)
JP (1) JP6901787B2 (es)
CN (1) CN108136209A (es)
CL (1) CL2018000573A1 (es)
CO (1) CO2018003454A2 (es)
HK (1) HK1256480A1 (es)
MX (2) MX2018002743A (es)
PE (1) PE20190380A1 (es)
WO (1) WO2017041054A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481409A4 (en) * 2016-07-11 2020-03-18 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) TREATMENT OF FOLLICULAR TONSILLITIS WITH PLANT EXTRACTS WITH CARNOSIC ACID
BR112019022184A2 (pt) * 2017-04-27 2020-05-12 Dsm Ip Assets B.V. Uso de extrato de withania somnifera para proteção contra doenças relacionadas à poluição do ar

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
US9265808B2 (en) * 2004-03-23 2016-02-23 Lifeline Nutraceuticals Corporation Compositions for alleviating inflammation and oxidative stress in a mammal
WO2006073042A1 (ja) * 2005-01-05 2006-07-13 Toagosei Co., Ltd. Ｎｒｆ２依存遺伝子の活性化剤
CA2648273A1 (en) * 2006-04-03 2007-10-11 Nestec S.A. Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same
AU2009223653B2 (en) 2008-03-10 2014-07-31 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
CN102164508B (zh) 2008-07-31 2015-04-01 嘉康利公司 具有增加的抗氧化活性的麝香葡萄组合物
JP2011057654A (ja) 2009-09-14 2011-03-24 Iwate Univ メタボリックシンドローム治療又は予防薬、及び脂肪細胞分化抑制方法
US20130023489A1 (en) 2009-12-24 2013-01-24 The Royal Institution For The Advancement Of Learning/Mcgill University Compositions and methods for preventing and treating diseases and environmentally induced health disorders
KR101254847B1 (ko) * 2010-05-27 2013-04-15 한림대학교 산학협력단 실리비닌(silibinin)을 포함하는 골다공증 치료 및 예방용 조성물
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
MX347457B (es) * 2012-01-16 2017-04-27 Héctor De Jesús Velez-Rivera Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares.
JP2013209351A (ja) * 2012-03-30 2013-10-10 Sunstar Inc 抗酸化機能亢進剤
US20140287071A1 (en) * 2013-01-17 2014-09-25 Lifevantage Corporation Veterinary supplements
WO2014151891A1 (en) 2013-03-14 2014-09-25 Walley Darlene Topical products
EP3021844B1 (en) * 2013-07-17 2019-11-13 Council of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
WO2016037971A1 (en) 2014-09-08 2016-03-17 Bios Line S.P.A. Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary

Also Published As

Publication number Publication date
JP6901787B2 (ja) 2021-07-14
CL2018000573A1 (es) 2019-01-11
MX2018002743A (es) 2018-06-06
CO2018003454A2 (es) 2018-08-31
JP2018529763A (ja) 2018-10-11
US11413269B2 (en) 2022-08-16
US20180250264A1 (en) 2018-09-06
HK1256480A1 (zh) 2019-09-27
WO2017041054A1 (en) 2017-03-09
MX2022009446A (es) 2022-09-05
CN108136209A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
CO2019008087A2 (es) Método para modular la actividad de inflamasoma e inflamación en el pulmón
AR102372A1 (es) Composición que comprende una mezcla de extractos vegetales o una mezcla de moléculas contenidas en dichos vegetales, y su utilización para actuar sobre el metabolismo glucídico y/o lipídico
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2018001006A1 (es) Composiciones farmacéuticas para terapia combinada (sol. divisional de n° 201701983)
CL2015003346A1 (es) Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas
CR20160093A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CL2015002083A1 (es) Composiciones herbicidas sinergicas
BR112016018085A8 (pt) composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CO2018005971A2 (es) Composición de regulador de crecimiento vegetal que tiene efecto sinérgico
CO2021001172A2 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
UY35597A (es) Compuestos y composiciones antimicrobianos
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
PE20190380A1 (es) Composiciones para activacion de nrf2 mejorada y sus metodos de uso
CU20160139A7 (es) Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos
CL2017001773A1 (es) Análogos de calcitonina para tratar enfermedades y trastornos.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.